Brad Briggs

Brad Briggs is the Executive Editor of StreetAuthority.com, StreetAuthority Insider. As Executive Editor, Brad manages the team of writers and editors responsible for our two free newsletters, StreetAuthority Daily and Dividend Opportunities as well as all of the free articles on our website, StreetAuthority.com. He is also the managing editor and a regular contributor for StreetAuthority's subscriber-only newsletter, StreetAuthority Insider. Brad joined StreetAuthority in 2008 and has used his journalism training to research and identify opportunities for investors ranging from energy to deep value to momentum plays. Dozens of his articles have been featured on Yahoo Finance, Nasdaq.com and MSN Money, among others.  Brad combines his years of experience in the financial industry along with a deep study of behavioral economics and investor psychology to stress the importance of minimizing the role of emotion in trading. Brad is a graduate of Baylor University and has received numerous individual and staff awards from the Society of Professional Journalists, the Texas Intercollegiate Press Association and the Houston Press Club. When not tracking the markets, Brad also enjoys traveling the world.

Analyst Articles

They say what’s past is prologue. So when history starts repeating itself like this, it’s wise to take notice. Mergers and acquisitions are picking up after a drought in activity for much of the past year. On Monday, Dell (Nasdaq: DELL) said it would buy computer-services provider Perot Systems (NYSE:… Read More

The U.S. isn’t the only country struggling to reform its health-care system. China has a big problem on its hands: 1.3 billion people and a system that has been ignored for decades. The World Health Organization recently ranked China’s health care 144th out of 190 countries. The country recently said… Read More

Biogen Idec (Nasdaq: BIIB) said it earned $143 million in the second quarter, or 49 cents a share, down -31% from last year, when the company earned 70 cents a share. The results reflect a $110 million expenditure on Fampridine, a new drug to treat multiple sclerosis. Excluding the purchase,… Read More